GTx,Inc. (NASDAQ:GTXI) Files An 8-K Other Events
Item 8.01 Other Events.
On November28, 2016, GTx,Inc. issued a press release announcing
that enobosarm achieved the pre-specified primary efficacy
endpoint in the 9 mg dose cohort from patients in both stage 1
and the ongoing stage 2 of its Phase 2 clinical trial in women
with advanced, estrogen receptor positive, androgen receptor
positive breast cancer.
A copy of the press release is furnished as Exhibit99.1 to this
Current Report.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits.
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release issued by GTx,Inc. dated November28, 2016 |
About GTx, Inc. (NASDAQ:GTXI)
GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage. GTx, Inc. (NASDAQ:GTXI) Recent Trading Information
GTx, Inc. (NASDAQ:GTXI) closed its last trading session down -0.055 at 0.785 with 23,903 shares trading hands.